Merck, Inc.
A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)
- Conditions
- Interventions
- First Posted Date
- 2024-06-14
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 686
- Registration Number
- NCT06459180
- Locations
- 🇦🇷
Sanatorio Allende - Cerro-Oncology ( Site 0106), Córdoba, Cordoba, Argentina
🇧🇷Centro de Hematologia e Oncologia ( Site 0203), Joinville, Santa Catarina, Brazil
🇧🇷Americas Centro de Oncologia Integrado ( Site 0202), Rio de Janeiro, Brazil
A Study of MK-6837 as a Monotherapy and Combination Therapy in Participants With Advanced/Metastatic Solid Tumors (MK-6837-001)
- Conditions
- Interventions
- First Posted Date
- 2024-06-14
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 100
- Registration Number
- NCT06460961
- Locations
- 🇨🇦
Princess Margaret Cancer Centre ( Site 2001), Toronto, Ontario, Canada
🇺🇸Atlantic Health System Morristown Medical Center ( Site 4001), Morristown, New Jersey, United States
🇺🇸Providence Portland Medical Center ( Site 4002), Portland, Oregon, United States
Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)
- Conditions
- Interventions
- First Posted Date
- 2024-06-13
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 300
- Registration Number
- NCT06456346
- Locations
- 🇯🇵
Fujita Health University ( Site 0613), Toyoake, Aichi, Japan
🇯🇵Ehime University Hospital ( Site 0612), Toon, Ehime, Japan
🇯🇵Hokkaido University Hospital ( Site 0601), Sapporo, Hokkaido, Japan
A Study to Evaluate the Efficacy and Safety of Enlicitide Decanoate (MK-0616, Oral PCSK9 Inhibitor) Compared With Ezetimibe or Bempedoic Acid or Ezetimibe and Bempedoic Acid in Adults With Hypercholesterolemia (MK-0616-018) CORALreef AddOn
- First Posted Date
- 2024-06-10
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 300
- Registration Number
- NCT06450366
- Locations
- 🇮🇱
Yitzhak Shamir Medical Center. ( Site 0702), Beer Yaakov, Israel
🇮🇱Rambam Health Care Campus ( Site 0700), Haifa, Israel
🇮🇱Meir Medical Center. ( Site 0703), Kfar Saba, Israel
Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)
- Conditions
- Interventions
- First Posted Date
- 2024-06-06
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 90
- Registration Number
- NCT06445972
- Locations
- 🇧🇷
Liga Norte Riograndense Contra o Câncer ( Site 8303), Natal, Rio Grande Do Norte, Brazil
🇺🇸University of Arizona Cancer Center-University of Arizona Cancer Center ( Site 8927), Tucson, Arizona, United States
🇺🇸Norton Cancer Institute - Downtown ( Site 8900), Louisville, Kentucky, United States
A Study of Nemtabrutinib in Participants With Moderate Hepatic Impairment (MK-1026-015)
- First Posted Date
- 2024-06-04
- Last Posted Date
- 2024-10-10
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 16
- Registration Number
- NCT06442436
- Locations
- 🇺🇸
Texas Liver Institute ( Site 0002), San Antonio, Texas, United States
🇺🇸Clinical Pharmacology of Miami ( Site 0003), Miami, Florida, United States
🇺🇸Orlando Clinical Research Center ( Site 0001), Orlando, Florida, United States
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
- Conditions
- Interventions
- First Posted Date
- 2024-05-28
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 1200
- Registration Number
- NCT06430801
- Locations
- 🇨🇦
ABP Research Services Corp. ( Site 0019), Oakville, Ontario, Canada
🇨🇳Peking University Third Hospital ( Site 3910), Beijing, Beijing, China
🇨🇳The First Affiliated hospital of Xiamen University ( Site 3924), XiaMen, Fujian, China
A Clinical Study of MK-2870 Alone or With Chemotherapy to Treat Gastrointestinal Cancers (MK-9999-02A)
- First Posted Date
- 2024-05-24
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 130
- Registration Number
- NCT06428409
- Locations
- 🇨🇳
The 900th Hospital of the Joint Logistics Support Force of the Chinese People's Liberation Army ( Si, Fuzhou, Fujian, China
🇨🇳Hunan Cancer Hospital-intervention department ( Site 0066), Changsha, Hunan, China
🇬🇧Royal Free Hospital ( Site 0262), London, England, United Kingdom
Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-043)
- Conditions
- Interventions
- First Posted Date
- 2024-05-24
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 342
- Registration Number
- NCT06428383
- Locations
- 🇮🇪
Children's Health Ireland (CHI) at Crumlin ( Site 1400), Dublin, Ireland
🇺🇸Le Bonheur Children's Hospital ( Site 0007), Memphis, Tennessee, United States
🇨🇴Clinica Somer-Unidad de Investigacion y Docencia ( Site 0607), Rionegro, Antioquia, Colombia
Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029)
- Conditions
- Interventions
- First Posted Date
- 2024-05-24
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 120
- Registration Number
- NCT06428396
- Locations
- 🇨🇱
Centro de Investigación del Maule ( Site 4106), Talca, Maule, Chile
🇺🇸Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital ( Site 0011), Marietta, Georgia, United States
🇺🇸CHRISTUS Highland ( Site 0005), Shreveport, Louisiana, United States